ELABELA ameliorates hypoxic/ischemic-induced bone mesenchymal stem cell apoptosis via alleviation of mitochondrial dysfunction and activation of PI3K/AKT and ERK1/2 pathways

• Published in: Stem cell research & therapy 2020-12, Vol.11 (1), p.541-541, Article 541
• Main Authors: Fu, Jiaying, Chen, Xuxiang, Liu, Xin, Xu, Daishi, Yang, Huan, Zeng, Chaotao, Long, Huibao, Zhou, Changqing, Wu, Haidong, Zheng, Guanghui, Wu, Hao, Wang, Wuming, Wang, Tong
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; Adenosine triphosphate; AKT protein; Animals; Apoptosis; Bax protein; Bcl-2 protein; Caspase-3; Cell survival; Cell viability; Cholecystokinin; ELABELA; Embryo cells; Embryonic stem cells; Experiments; Extracellular signal-regulated kinase; Flow cytometry; G proteins; Health aspects; Heart attack; Hypoxia; Hypoxic/ischemic; Ischemia; Ligands; MAP Kinase Signaling System; Membrane potential; Membrane proteins; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Mitochondria; Mitochondria - metabolism; Myocardial infarction; Peptide Hormones; Peptides; Phosphatidylinositol 3-Kinases - genetics; Phosphatidylinositol 3-Kinases - metabolism; Phosphorylation; Pluripotency; Proteins; Proto-Oncogene Proteins c-akt - genetics; Proto-Oncogene Proteins c-akt - metabolism; Putative receptor protein related to the angiotensin receptor AT1 endogenous ligand; Rats; Stem cell transplantation; Stem cells
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-020-02063-1

Mesenchymal stem cells (MSCs) have exerted their brilliant potential to promote heart repair following myocardial infarction. However, low survival rate of MSCs after transplantation due to harsh conditions with hypoxic and ischemic stress limits their therapeutic efficiency in treating cardiac dysfunction. ELABELA (ELA) serves as a peptide hormone which has been proved to facilitate cell growth, survival, and pluripotency in human embryonic stem cells. Although ELA works as an endogenous ligand of a G protein-coupled receptor APJ (Apelin receptor, APLNR), whether APJ is an essential signal for the function of ELA remains elusive. The effect of ELA on apoptosis of MSCs is still vague. We studied the role of ELABELA (ELA) treatment on the anti-apoptosis of MSCs in hypoxic/ischemic (H/I) conditions which mimic the impaired myocardial microenvironment and explored the possible mechanisms in vitro. MSCs were obtained from donated rats weighing between 80~120 g. MSCs were exposed to serum-free and hypoxic (1% O ) environments for 24 h, which mimics hypoxic/ischemic damage in vivo, using serum-containing normoxic conditions (20% O ) as a negative control. MSCs that were exposed to H/I injury with ELA processing were treated by 5 μM of ELA. Cell viability and apoptosis of MSCs were evaluated by CCK8 and flow cytometry, respectively. Mitochondrial function of MSCs was also assessed according to mitochondrial membrane potential (MMP) and ATP content. The protein expression of key kinases of the PI3K/AKT and ERK1/2 signaling pathways involving t-AKT, p-AKT, t-ERK1/2, and p-ERK1/2, as well as apoptosis-related protein expression of Bcl-2, Bax, and cleaved Caspase 3, were monitored by Western blot. We found that ELA treatment of H/I-induced MSCs improved overall cell viability, enhanced Bcl/Bax expression, and decreased Caspase 3 activity. ELA inhibited H/I-induced mitochondrial dysfunction by increasing ATP concentration and suppressing the loss of mitochondrial transmembrane potential. However, this anti-apoptotic property of ELA was restrained in APJ-silenced MSCs. Additionally, ELA treatment induced the phosphorylation of AKT and ERK, while the blockade of PI3K/AKT and ERK1/2 pathways with respective inhibitors, LY294002 and U0126, suppressed the action of ELA. ELA positively affected on the survival of MSCs and exhibited anti-apoptotic characteristics when exposed to hypoxic/ischemic condition in vitro. Also, the function of ELA was correlated with the APJ recept